Fiskars’ Q3 adjusted EBIT of EUR 24.3m came 1% above LSEG Data & Analytics consensus expectations.
Redeye notes that Gasporox's report came in below Redeye Estimates (RRe) across the board while prod...
Redeye comments on Sleep Cycle's Q3 2024 report, which showed a growth rate of 8.
Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too ...
Redeye comments on Polygiene Group´s third quarter of the year.
Redeye provides its initial take on ADDvise’s Q3 2024 report, which came in broadly below our estima...
XVIVO delivers a Q3 that aligns with our expectations but is below market expectations due to FX hea...
Redeye comments on Evolution’s Q3-results which was close to our estimates and the company looks to ...
Redeye comments on SHH´s third quarter of the year.
Redeye’s first take on the Q3 report this morning. There were considerable changes in sales in the d...
Sales -1% y-o-y, -3% vs. ABGSCe EBIT of SEK 63m, 75% vs.
Redeye will likely increase its forecasts and Base Case following a solid Q3 report from Addnode.
Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal inten...
Redeye continues to see a compelling long-term investment case.
Atria delivered a strong Q3, with adjusted EBIT 35% above LSEG Data & Analytics consensus.
Limited estimate revisions Growth appears more capital-light than history suggests Trading at '25e E...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Redeye provides a research update following the Q4 report recently published by Newbury.
Hyresintäkterna sjönk något till 847 mkr, främst drivet av tidigare avyttrade fastigheter.
Redeye provides a note about CLS’s decision to concentrate fully on its neurosurgery business.
